4.6 Article

Single-cell heterogeneity in Sezary syndrome

期刊

BLOOD ADVANCES
卷 2, 期 16, 页码 2115-2126

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/bloodadvances.2018022608

关键词

-

资金

  1. Danish Cancer Society
  2. Fight Cancer Program (Knaek Cancer)
  3. Novo Nordisk Research Foundation
  4. Novo Nordic Foundation Tandem Program
  5. Lundbeck Foundation
  6. Danish Council for Independent Research (Danmarks Frie Forskningsfond)
  7. Sapere Aude Talent Grant [DFF-4092-00122]
  8. LINAK A/S
  9. Dansk Kraeftforsknings Fond

向作者/读者索取更多资源

Sezary syndrome (SS) is an aggressive leukemic variant of cutaneous T-cell lymphoma (CTCL) with a median life expectancy of less than 4 years. Although initial treatment responses are often good, the vast majority of patients with SS fail to respond to ongoing therapy. We hypothesize that malignant T cells are highly heterogeneous and harbor subpopulations of SS cells that are both sensitive and resistant to treatment. Here, we investigate the presence of single-cell heterogeneity and resistance to histone deacetylase inhibitors (HDACi) within primary malignant T cells from patients with SS. Using single-cell RNA sequencing and flow cytometry, we find that malignant T cells from all investigated patients with SS display a high degree of single-cell heterogeneity at both the mRNA and protein levels. We show that this heterogeneity divides the malignant cells into distinct subpopulations that can be isolated by their expression of different surface antigens. Finally, we show that treatment with HDACi (suberanilohydroxamic acid and romidepsin) selectively eliminates some subpopulations while leaving other subpopulations largely unaffected. In conclusion, we show that patients with SS display a high degree of single-cell heterogeneity within the malignant T-cell population, and that distinct subpopulations of malignant T cells carry HDACi resistance. Our data point to the importance of understanding the heterogeneous nature of malignant SS cells in each individual patient to design combinational and new therapies to counter drug resistance and treatment failure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据